Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Insufficient chart data. Estimates will improve as the show charts.
- Per-Episode Audience
Est. listeners per new episode within ~30 days
N/A🎙 Daily cadence·373 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
N/A - Active Followers
Loyal subscribers who consistently listen
N/A
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 24 epsHosts
Recent guests
Recent episodes
393.Why Most MedTech Startups Lose After Finding Product Market Fit and Never Build Durable Market Power
Jun 24, 2026
Unknown duration
392. Improving Breast Surgery Outcomes Through a Prehabilitation Platform with Saahil Mehta of Plexāā
Jun 22, 2026
Unknown duration
391. Why Early Adopters Are a Risk for Medtech Startups Scaling to Mainstream Market
Jun 17, 2026
Unknown duration
390. Neuromod: How non-invasive ultrasound neuromodulation could change autoimmune disease treatment with Nishant Doctor of Surf Therapeutics
Jun 15, 2026
Unknown duration
389.Should You Quit Your Job for a Startup? The Psychology of Startups vs Corporations Through the Barbarians to Bureaucrats Framework
Jun 10, 2026
29m 07s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
Resolving iTunes ID\u2026 if this persists, the podcast may not be indexed on Apple Podcasts.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 6/24/26 |  393.Why Most MedTech Startups Lose After Finding Product Market Fit and Never Build Durable Market Power | Why Product Market Fit Is Only the Beginning!Most startups spend years chasing traction.Very few spend enough time understanding what happens after they achieve it.In this solo episode, Omar Khateeb explains why product-market fit creates opportunity but does not create protection. Growth attracts customers, but it also attracts competitors, capital, strategic interest, and market attention.The conversation explores category leadership, market control, ecosystem building, narrative ownership, flywheel economics, and why sustainable advantage comes from shaping the environment around a category rather than simply participating in it.Omar also shares practical lessons from MedTech, software, AI, and platform businesses that demonstrate why the companies that create categories are not always the companies that ultimately dominate them.A powerful discussion on strategy, competitive positioning, and long-term market leadership.This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Episode Breakdown:00:00 Why Traction Can Be Dangerous01:08 Intro + The Real Purpose of Traction03:15 Why Most Startups Fail05:00 Traction vs Category Leadership06:30 Growth Creates Visibility and Competition09:40 Why Growth Is Exposure, Not Protection12:46 Market Share vs Category Control14:53 The Power of Narrative Control18:13 Building an Ecosystem Moat21:20 The Capital Flywheel Explained23:05 Why Standards Create Market Power25:09 How Challengers Beat Market Leaders27:23 Early Signs of Commoditization29:20 Why Category Leadership Must Be Managed31:00 Two Companies, Two Different Outcomes32:06 Final Lessons on Traction and Leadership33:00 OutroAre you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.Subscribe to our Youtube Channelhttps://www.youtube.com/@thestateofmedtechSubscribe to our LinkedIn Newsletterhttps://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/Follow The State of MedTech onLinkedIn https://www.linkedin.com/company/thestateofmedtech/Instagram https://www.instagram.com/stateofmedtech/TikTok https://www.tiktok.com/@stateofmedtechpodX https://x.com/stateofmedtechFacebook https://www.facebook.com/stateofmedtechFollow Omar M. Khateeb onLinkedIn https://www.linkedin.com/in/okhateeb/Instagram https://www.instagram.com/omar.m.khateeb/TikTok https://www.tiktok.com/@omar.m.khateebX https: https://x.com/OmarMKhateebFacebook https://www.facebook.com/OmarMKhateeb#medtech #category #marketleadership #startupstrategy #businessgrowth #leadership | — | ||||||
| 6/22/26 |  392. Improving Breast Surgery Outcomes Through a Prehabilitation Platform with Saahil Mehta of Plexāā | Most surgical innovation focuses on what happens during or after a procedure.Saahil Mehta believes the bigger opportunity may exist before surgery ever starts.In this episode, Omar Khateeb speaks with the Founder of Plexāā about prehabilitation, tissue conditioning, breast reconstruction, patient education, and the role preparation plays in long-term recovery.The discussion examines how heat shock proteins can improve tissue resilience, why surgical complications often delay treatment, and how structured preparation programs can give patients more control over their outcomes.Saahil also shares how Plexāā is combining medical devices, digital health, and behavioral engagement to build a new category around surgical readiness.Healthcare has spent decades optimizing recovery.Preparation may be the next frontier.This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Episode Breakdown:00:00 Why Surgery Recovery Starts Before Surgery00:01 Intro + The Problem with Pre-Op Care02:00 From Plastic Surgeon to MedTech Founder04:45 Why Patients Ask the Same Question Before Surgery06:58 The Hidden Problem in Breast Reconstruction09:00 What is Skin Necrosis?11:15 How Delayed Healing Impacts Cancer Treatment12:30 The Science of Heat Shock Proteins14:45 The Origin of Bloom4316:50 How the Device Works18:25 Why Prehabilitation Matters20:56 The Free Bloom43 App Explained22:19 The Story Behind the Bloom43 Name24:15 Why Patients Only Use It the Night Before Surgery26:03 Why a Heating Pad Isn't the Same Thing28:07 Commercial Launch and Patient Access30:20 Hospital Adoption and Future Reimbursement33:16 Clinical Evidence and Ongoing Research36:10 Mayo Clinic Collaboration and C-Section Expansion38:00 Why Women's Health is the Perfect Beachhead40:37 AI, Patient Data, and Personalized Surgical Prep42:46 Wearables, Recovery, and the Future of Surgery44:42 Building the Future of Pre-Op Care47:00 What's Next for Plexo and Bloom4348:15 Final Thoughts49:00 OutroAre you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.Subscribe to our Youtube Channelhttps://www.youtube.com/@thestateofmedtechSubscribe to our LinkedIn Newsletterhttps://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/Follow The State of MedTech onLinkedIn https://www.linkedin.com/company/thestateofmedtech/Instagram https://www.instagram.com/stateofmedtech/TikTok https://www.tiktok.com/@stateofmedtechpodX https://x.com/stateofmedtechFacebook https://www.facebook.com/stateofmedtechFollow Omar M. Khateeb onLinkedIn https://www.linkedin.com/in/okhateeb/Instagram https://www.instagram.com/omar.m.khateeb/TikTok https://www.tiktok.com/@omar.m.khateebX https: https://x.com/OmarMKhateebFacebook https://www.facebook.com/OmarMKhateeb#breastcancer #medtech #surgicalinnovation #healthcareinnovation #womenshealth | — | ||||||
| 6/17/26 |  391. Why Early Adopters Are a Risk for Medtech Startups Scaling to Mainstream Market | In this solo episode, Omar Khateeb explores why many startups struggle immediately after gaining traction.The challenge is rarely the technology.The challenge is the buyer.Early adopters and mainstream customers make decisions for completely different reasons. One group rewards innovation and vision. The other rewards certainty, references, evidence, and proven outcomes.The conversation examines the psychology behind technology adoption, the importance of reference customers, the power of focus, and why credibility becomes the most valuable asset when companies attempt to cross the chasm.Omar also explains how trust compounds, why broader markets often slow growth, and how market leadership is built through density rather than reach.A practical framework for founders, operators, investors, and commercial leaders navigating the journey from adoption to scale.This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Episode Breakdown:00:00 Why Most Startups Fail After Early Success01:03 Intro + Crossing the Chasm Explained03:15 The Technology Adoption Curve05:50 Innovators vs Mainstream Buyers08:40 Why Better Products Still Fail11:20 The Early Adopter Trap13:00 Why Product-Market Fit Isn't Enough15:15 Market Engineering Before Launch17:30 Selling Vision vs Selling Proof20:10 The Bowling Alley Strategy22:00 Why Focus Beats Going Broad24:15 Building Trust Through References26:00 The Whole Product Concept28:20 Why Mainstream Buyers Resist Change30:10 Chasm Readiness Checklist31:45 Scaling Trust and Reducing Risk33:00 The One Segment Strategy34:06 Final Thoughts + OutroAre you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.Subscribe to our Youtube Channelhttps://www.youtube.com/@thestateofmedtechSubscribe to our LinkedIn Newsletterhttps://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/Follow The State of MedTech onLinkedIn https://www.linkedin.com/company/thestateofmedtech/Instagram https://www.instagram.com/stateofmedtech/TikTok https://www.tiktok.com/@stateofmedtechpodX https://x.com/stateofmedtechFacebook https://www.facebook.com/stateofmedtechFollow Omar M. Khateeb onLinkedIn https://www.linkedin.com/in/okhateeb/Instagram https://www.instagram.com/omar.m.khateeb/TikTok https://www.tiktok.com/@omar.m.khateebX https: https://x.com/OmarMKhateebFacebook https://www.facebook.com/OmarMKhateeb#medtech #gotomarket #chasm #startupstrategy #marketexpert | — | ||||||
| 6/15/26 |  390. Neuromod: How non-invasive ultrasound neuromodulation could change autoimmune disease treatment with Nishant Doctor of Surf Therapeutics | Omar Khateeb speaks with Nishant Doctor, Founder, CEO, and CTO of Surf Therapeutics, about the next frontier of neurotechnology: using ultrasound neuromodulation to target inflammation.Nishant breaks down the science behind the cholinergic anti-inflammatory pathway, why the splenic nerve may offer a more direct target than the vagus nerve, and how non-invasive stimulation could create a different treatment path for rheumatoid arthritis patients.The episode also covers capital efficiency, first-in-human studies, patient usability, autoimmune disease, and why Surf is focused on building a therapy that could be safer, easier, and more accessible than invasive alternatives.A powerful conversation on bioelectronic medicine, chronic disease, and the future of non-invasive MedTech.This podcast is for informational and educational purposes only and does not constitute financial, investment, legal, or medical advice. The views and opinions expressed by hosts and guests are their own and do not necessarily reflect those of State of MedTech LLC. Nothing discussed on this podcast should be interpreted as a recommendation to buy, sell, or hold any investment or security. Listeners should conduct their own due diligence and consult with a qualified financial advisor, attorney, or other professional before making any financial or investment decisions.Episode Breakdown00:00 How One Minute of Stimulation Can Reduce Inflammation01:34 Intro + Why Drug Alternatives Matter03:23 Nishant Doctor’s Journey Into Neuromodulation05:23 Neuromodulation vs Neurotechnology Explained08:15 Neuralink, BCI, and the Rise of NeuroTech09:07 Building Through Market Cycles13:37 The Origin Story of Surf Therapeutics15:23 Inflammation, Healthspan, and Chronic Disease17:52 The Science Behind the Anti-Inflammatory Pathway18:50 Why Vagus Nerve Stimulation Works20:18 Why Surf Chose a Non-Invasive Approach21:31 The Problem with Current Treatment Options22:44 Going Directly to the Splenic Nerve24:26 Vagus Nerve Side Effects Explained26:03 Biohacking, Longevity, and Vagus Nerve Devices27:15 How Surf’s Technology Works29:40 Capital Efficiency and Startup Execution32:02 Why Testing Beats Product Perfection33:58 Build Fast, Test Fast, Learn Fast37:20 Why Rheumatoid Arthritis Was the First Target39:38 The Rheumatoid Arthritis Opportunity40:02 Understanding Rheumatoid Arthritis41:38 Expanding Beyond a Single Disease43:31 The Future of Inflammation Therapy44:55 Why the Company is Called Surf46:16 Clinical Progress and Upcoming Milestones48:02 Strategic Interest and Future Opportunities48:38 OutroAre you a medtech CEO in need of some marketing help attracting investors, growing sales pipeline, and more? Go to GrowMyMedtech.com to book time for a free analysis.Subscribe to our Youtube Channelhttps://www.youtube.com/@thestateofmedtechSubscribe to our LinkedIn Newsletterhttps://www.linkedin.com/newsletters/state-of-medtech-pod-7328860752952352770/Follow The State of MedTech onLinkedIn https://www.linkedin.com/company/thestateofmedtech/Instagram https://www.instagram.com/stateofmedtech/TikTok https://www.tiktok.com/@stateofmedtechpodX https://x.com/stateofmedtechFacebook https://www.facebook.com/stateofmedtechFollow Omar M. Khateeb onLinkedIn https://www.linkedin.com/in/okhateeb/Instagram https://www.instagram.com/omar.m.khateeb/TikTok https://www.tiktok.com/@omar.m.khateebX https: https://x.com/OmarMKhateebFacebook https://www.facebook.com/OmarMKhateeb#neurotech #neuromodulation #rheumatoidarthritis #medtech #healthcareinnovation | — | ||||||
| 6/10/26 |  389.Should You Quit Your Job for a Startup? The Psychology of Startups vs Corporations Through the Barbarians to Bureaucrats Framework✨ | career satisfactionprofessional growth+5 | — | State of MedTech | — | startupscorporations+8 | — | 29m 07s | |
| 6/8/26 |  388.Market Engineering with Bruce Cleveland of Traction Gap Partners✨ | market creationcategory design+4 | Bruce Cleveland | Traction Gap PartnersOracle+3 | — | market engineeringcategory leaders+5 | — | 1h 11m 36s | |
| 6/3/26 |  387. This Month in MedTech: Q1 Earnings, M&A Momentum, and the Rise of Focused Strategics✨ | MedTech market signalsQ1 earnings+5 | Nicholas Talamantes | Life Science IntelligenceBoston Scientific+5 | — | MedTechM&A+6 | — | 1h 22m 03s | |
| 6/1/26 |  386.Matt Curl of Apollo.io on Why Modern Go To Market Is Becoming the Biggest Competitive Advantage in Business✨ | go to marketAI+4 | Matt Curl | Apollo.io | — | AI driven personalizationreal time data+5 | — | 59m 28s | |
| 5/27/26 |  385. How to manage your board using the Elephant Slide✨ | Elephant Slide frameworkMedTech leadership+4 | — | RA Capital | — | Elephant SlideMedTech+5 | — | 25m 23s | |
| 5/25/26 |  384: Venture: Virginia Giddings of Edwards Lifesciences & Deborah Kilpatrick of Sonder Capital✨ | MedTech innovationventure capital+5 | Deborah K.Virginia Giddings | Edwards LifesciencesSonder Capital | — | MedTechventure capital+5 | — | 1h 18m 21s | |
| 5/20/26 |  383. Founder Mode Was Always Barbarian Energy: Hardball Leadership and Market Conquest✨ | leadershipmarket strategy+4 | — | IntuitiveState of MedTech LLC | — | barbarian energyhardball strategy+5 | — | 58m 51s | |
| 5/18/26 |  382.Cardiology's Blind Spot: Why Cardiac Intelligence Platforms Are Redefining Early Detection with Chris Darland, Peerbridge Health✨ | cardiologyAI in healthcare+3 | Chris Darland | Peerbridge Health | — | cardiac intelligenceAI+3 | — | 47m 43s | |
| 5/14/26 |  381.Chamath Was Right: Attention Is the Operating System of AI, Media, and Markets✨ | attentionAI+5 | — | GoogleState of MedTech LLC | — | attention mechanismsPageRank+8 | — | 44m 47s | |
| 5/11/26 |  380. Urology: MRI-native robotic platform for prostate cancer with Fazila Seker, CEO of Insight Medbotics✨ | prostate cancerMedTech innovation+3 | Fazila Seker | Insight Medbotics | — | prostate cancerMRI+5 | — | 56m 38s | |
| 5/6/26 |  379. This Month in MedTech 2026: Cardiovascular M&A, Medtronic’s $100M Bet, and the Platform Wars✨ | MedTech fundingCardiovascular M&A+3 | — | MedtronicPulnovo | China | MedTechfunding trends+7 | — | 51m 11s | |
| 5/4/26 |  378. TechMed: Autonomous Surgery Leadership with Nick Damiano of Andromeda Surgical✨ | autonomous surgerysurgical robotics+4 | Nick Damiano | Andromeda Surgical | — | autonomous surgerysurgical robotics+5 | — | 51m 22s | |
| 4/29/26 |  377. Exits: 7 Lessons from $17B in Medtech Exits That Every Founder Must Know✨ | MedTech exitsfounder strategy+3 | Omar Khateeb | MarketcraftState of MedTech LLC | — | MedTechexits+5 | — | 37m 55s | |
| 4/27/26 |  376. Venture: Dennis McWilliams of Santé Ventures✨ | medtech investmentventure capital+4 | Dennis McWilliams | Santé VenturesApollo Endosurgery+7 | — | medtechventure capital+5 | — | 1h 02m 55s | |
| 4/22/26 |  375. Crossing the Chasm and The Technology Adoption Curve for Medtech Founders✨ | technology adoptionMedTech growth+3 | Omar Khateeb | Marketcraft | — | technology adoption curveearly adopters+3 | — | 37m 05s | |
| 4/20/26 |  374. Venture: What MVM Partners Really Wants in a MedTech Company with Kyle Dempsey✨ | medtech investingcommercialization+3 | Kyle Dempsey | MVM PartnersMedTech | — | medtechinvestment+5 | — | 1h 08m 29s | |
| 4/15/26 |  373.How Market Engineering Gets Medtech Startups Funded✨ | MedTech startupsmarket engineering+3 | Omar Khateeb | Marketcraft | — | MedTechstartups+5 | — | 38m 23s | |
| 4/13/26 |  372. Corporate Venture: Hikma Pharma's VP Corporate Development & Ventures Lana Ghanem on Investing in Medtech✨ | Corporate VentureMedTech Investment+3 | Lana Ghanem | Hikma PharmaceuticalsHikma Ventures | Middle EastNorth Africa | corporate ventureMedTech+5 | — | 33m 27s | |
| 4/8/26 |  371.Digital Surgery with George Murgatroyd GM & VP of Medtronic on Digitizing the Operating Room✨ | digital surgeryAI in healthcare+5 | George Murgatroyd | MedtronicTouch Surgery+1 | — | digital surgeryAI assistant+8 | Donna | 1h 22m 34s | |
| 4/6/26 |  370.MD&M 2026 Keynote: Are we innovating or iterating? $6.1B worth of advice from Ray Cohen and Tom West moderated by Omar M. Khateeb✨ | innovationiteration+3 | Raymond W. CohenThomas A. West | Spiro MedicalNalu Medical | — | medtechinnovation+3 | — | 1h 16m 15s | |
| 4/1/26 |  369. This Month in MedTech: What Q1 2026 Reveals About Where the Market Is Going✨ | MedTech market shiftsM&A activity+5 | Nicholas Talamantes | Boston ScientificMedtronic+4 | — | MedTechM&A+5 | — | 48m 59s | |
Showing 25 of 368
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.